Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy?

Su‐Shun ‐S Lo*, Hwei‐Chung ‐C Wang, Yi‐Ming ‐M Shyr, Wing‐Yiu ‐Y Lui

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

In order to know whether neoadjuvant chemotherapy would change the hormonal receptor status of primary breast cancer, 10 patients with locally advanced breast cancer treated with neoadjuvant CEF (endoxan, epirubicin, 5‐fluorouracil) were studied. Tissue was obtained by incisional biopsy before chemotherapy and by mastectomy after three courses of treatment. All the specimens were subjected to histology study and the tests of estrogen (ER) and progesterone (PgR) receptors. The results revealed that the only hormonal status of one out of 10 tumors was altered. Among the 10 tumors, 2 out of 10 ER and 3 out of 10 PgR were changed after neoadjuvant CEF. From our results together with others findings, it is concluded that neoadjuvant CEF dose not significantly change the hormonal receptor status of primary breast cancer. The hormonal receptor assay is unnecessary before chemotherapy. © 1994 Wiley‐Liss, Inc.

Original languageEnglish
Pages (from-to)94-96
Number of pages3
JournalJournal of Surgical Oncology
Volume57
Issue number2
DOIs
StatePublished - Oct 1994

Keywords

  • breast cancer
  • hormonal receptor
  • neoadjuvant chemotherapy

Fingerprint

Dive into the research topics of 'Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy?'. Together they form a unique fingerprint.

Cite this